Pegvisomant: A novel pharmacotherapy for the treatment of acromegaly

Expert Opinion on Biological Therapy

Volumn 4, Issue 3, 2004, Pages 421-425

  Paisley, Angela N ^a   Trainer, Peter ^a   Drake, William ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Acromegaly; Growth hormone receptor antagonist; Insulin like growth factor I; Pegvisomant

Indexed keywords

GROWTH HORMONE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFICACY; EUROPE; HUMAN; LIVER FUNCTION; LIVER TOXICITY; PRESCRIPTION; REVIEW; TACHYPHYLAXIS; UNITED STATES;

ACROMEGALY; ANIMALS; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; PITUITARY NEOPLASMS; RECEPTORS, SOMATOTROPIN;

EID: 1542677586     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.3.421     Document Type: Review

References (24)

1. HOLDAWAY IM, RAJASOORYA C: Epidemiology of acromegaly. Pituitary (1999) 2:29-41.
2. RAJASOORYA C, HOLDAWAY IM, WRIGHTSON P, SCOTT DJ, IBBERTSON HK: Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. (1994) 41:95-102.
3. ORME SM, MCNALLY RJQ, CARTWRIGHT RA, BELCHETZ PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. J. Clin. Endocrinol. Metab. (1998) 83:2730-2734.
4. BATES AS, VAN'T HOFF W, JONES JM, CLAYTON RM: An audit of outcome of treatment in acromegaly. Q. J. Med. (1993) 86:293-299.
5. ABOSCH A, BLAKE TYRELL J, LAMBORN KR, HANNEGAN LT, APPLEBURY CB, WILSON CB: Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J. Clin. Endocrinol. Metab. (1998) 83:3411-3418.
6. HOLDAWAY IM, RAJASOORYA CR, GAMBLE GD, STEWART AW: Long-term treatment outcome in acromegaly. Growth Horm. IGF Res. (2003) 13:185-192.
7. GIUSTINA A, BARKAN A, CASANEUVA FF et al.: Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. (2000) 85:526-529.
8. TRAINER PJ: Acromegaly-consensus, what consensus? J. Clin. Endocrinol. Metab. (2002) 87:3534-3536.
9. COLAO A, CUOCOLO A, MARZULLO P et al.: Is the acromegalic cardiomyopathy reversible? Effect of a 5-year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J. Clin. Endocrinol. Metab. (2001) 86:1551-1557.
10. SWEARINGEN B, BARKER FG, KATZNELSON L et al: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. (1998) 83(10):3419-3426.
11. GITTOES NJL, SHEPPARD MC, JOHNSON AP, STEWART PM: Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon. Q. J. Med. (1999) 92:741-745.
12. SHEAVES R, JENKINS P, BLACKBURN P et al.: Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin. Endocrinol. (Oxf.) (1996) 45:407-413.
13. BIERMASZ NR, VAN DULKEN H, ROELFSEMA F: Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J. Clin. Endocrinol. Metab. (2000) 85:2476-2482.
14. KOPCHICK JJ, PARKINSON C, STEVENS EC, TRAINER PJ: Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev. (2002) 23(5):623-646.
15. VAN DER LELY AJ, LAMBERTS SWJ, BARKER A et al.: A six week, double blind, placebo controlled study of a growth hormone antagonist, B2036-PEG (Trovert), in acromegalic patients. 80th Annual Meeting of the Endocrine Society, New Orleans, LA, USA (1998) Abstract OR4-1.
16. TRAINER PJ, DRAKE WM, KATZNELSON L et al.: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. (2000) 342:1171-1177.
17. VAN DER LELY AJ, KENT HUTSON R, TRAINER PJ et al.: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 358:1754-1759.
18. FREDA PU: Somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. (2002) 87:3013-3018.
19. ABS R, VERHELST J, MAITER D et al.: Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. (1998) 83:374-378.
20. HANSEN I, TSALIKIAN E, BEAUFRERE B, GERICH J, HAYMOND M, RIZZA R: Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am. J. Phys. (1986) 250:E269-E273.
21. RANDLE PJ, GARLAND PB, HALES CN, NEWSHOLME EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbance of diabetes mellitus. Lancet (1963) 1:785-789.
22. ROSE DR, CLEMMONS DR: Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm. IGF Res. (2002) 12:418-424.
23. DRAKE WM, ROWLES SV, ROBERTS ME et al.: Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur. J. Endocrinol. (2003) 149:521-527.
24. CLEMMONS DR, BARKAN AL, MELMED S et al.: Pegvisomant improves glucose homeostasis in patients with acromegaly previously treated with octreotide LAR. 85th Annual Meeting of the Endocrine Society, Philadelphia, PA, USA (2003) P2-341.